Country: Եվրոպական Միություն
language: անգլերեն
source: EMA (European Medicines Agency)
inactivated bluetongue virus, serotype 1, strain BTV-1/ALG2006/01 E1 RP, inactivated bluetongue virus, serotype 8, strain btv-8/bel2006/02
Zoetis Belgium SA
QI02AA08
inactivated bluetongue virus, serotypes 1 and 8
Cattle
bluetongue virus, Immunologicals, Immunologicals for bovidae, Cattle, Inactivated viral vaccines
Active immunisation of cattle from 3 months of age for the prevention* of viraemia caused by Bluetongue Virus (BTV), serotypes 1 and 8.*(Cycling value (Ct) ≥ 36 by a validated RT-PCR method, indicating no presence of viral genome).
Revision: 6
Authorised
2012-03-08
16 B. PACKAGE LEAFLET 17 PACKAGE LEAFLET: ZULVAC 1+8 BOVIS SUSPENSION FOR INJECTION FOR CATTLE 1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT Marketing authorisation holder: Zoetis Belgium SA Rue Laid Burniat 1 1348 Louvain-la-Neuve BELGIUM Manufacturer responsible for batch release: Zoetis Manufacturing & Research Spain, S.L. Ctra. Camprodón s/n "la Riba" 17813 Vall de Bianya Girona SPAIN 2. NAME OF THE VETERINARY MEDICINAL PRODUCT Zulvac 1+8 Bovis suspension for injection for cattle 3. STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S) Each 2 ml dose contains: ACTIVE SUBSTANCE: Inactivated bluetongue virus, serotype 1, strain BTV-1/ALG2006/01 E1 RP* ≥ 1 Inactivated bluetongue virus, serotype 8, strain BTV-8/BEL2006/02 RP* ≥ 1 *Relative Potency by a mice potency test compared to a reference vaccine that was shown efficacious in cattle. ADJUVANTS: Aluminium hydroxide 4 mg (Al 3+ ) Saponin 1 mg EXCIPIENT: Thiomersal 0.2 mg 4. INDICATION(S) For active immunisation of cattle from 3 months of age for the prevention* of viraemia caused by bluetongue virus (BTV), serotypes 1 and 8. *(Cycling value (Ct) ≥ 36 by a validated RT-PCR method, indicating no presence of viral genome). Onset of immunity: 21 days after completion of the primary vaccination course. Duration of immunity: 12 months after completion of the primary vaccination course. 18 5. CONTRAINDICATIONS None. 6. ADVERSE REACTIONS A transient increase in rectal temperature, not exceeding 2.7 C, was commonly observed during the 48 hours following vaccination in field safety studies. Local reactions of < 2 cm diameter were very commonly observed while reactions of up to 5cm diameter were commonly observed after administration of a single dose in field safety studies. These resolved within a maximum of 25 days. Local reactions may increase slightly following the second dose in this case lasting up to 15 days. Local reactions of up to 5 cm diameter we read_full_document
1 ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 2 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Zulvac 1+8 Bovis suspension for injection for cattle 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each 2 ml dose contains: ACTIVE SUBSTANCE(S): Inactivated bluetongue virus, serotype 1, strain BTV-1/ALG2006/01 E1 RP* ≥ 1 Inactivated bluetongue virus, serotype 8, strain BTV-8/BEL2006/02 RP* ≥ 1 *Relative Potency by a mice potency test compared to a reference vaccine that was shown efficacious in cattle. ADJUVANT(S): Aluminium hydroxide 4 mg (Al 3+ ) Saponin 1 mg EXCIPIENT(S): Thiomersal 0.2 mg For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Suspension for injection. Off-white or pink liquid 4. CLINICAL PARTICULARS 4.1 TARGET SPECIES Cattle 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES For active immunisation of cattle from 3 months of age for the prevention* of viraemia caused by bluetongue virus (BTV), serotypes 1 and 8. *(Cycling value (Ct) ≥ 36 by a validated RT-PCR method, indicating no presence of viral genome). Onset of immunity: 21 days after completion of the primary vaccination course Duration of immunity: 12 months after completion of the primary vaccination course. 4.3 CONTRAINDICATIONS None. 4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES No information is available on the use of the vaccine in seropositive animals including those with maternally derived antibodies. If used in other domestic and wild ruminant species that are considered at risk of infection, its use in these species should be undertaken with care and it is advisable to test the vaccine on a small number 3 of animals prior to mass vaccination. The level of efficacy for other species may differ from that observed in cattle. 4.5 SPECIAL PRECAUTIONS FOR USE Special precautions for use in animals Vaccinate only healthy animals. Special precautions to be taken by the person administering the veterinary medicinal product to animals None. 4.6 ADVERSE REACTIONS (FREQUENCY AND SERIOUSNESS) A transient increase in rectal read_full_document